MedTrace Logo

Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis

NCT01381055 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2017-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether pentoxifylline associated to pentavalent antimony has a higher cure rate than pentavalent antimony alone in the treatment of cutaneous leishmaniasis.

Conditions

  • Cutaneous Leishmaniasis

Interventions

DRUG

Pentoxifylline

Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.

DRUG

Placebo

Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.

Sponsors & Collaborators

  • Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais (INCT-DT)

    collaborator UNKNOWN

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

    collaborator OTHER_GOV

  • Federal University of Bahia

    collaborator OTHER

  • Paulo Roberto Lima Machado

    lead OTHER

Principal Investigators

  • Paulo Roberto L Machado, MD, PhD · Federal University of Bahia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-01-31
Completion
2015-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381055 on ClinicalTrials.gov